Supplementary Material for: New perspectives in the treatment of inflammatory myofibroblastic tumor with ALK translocation. Case Report.

Inflammatory myofibroblastic tumor is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases where surgery is not possible due to localization or if it presents with metastatic disease. Approximately 50% of IMTs will exhibit ALK translocation, providing a therapeutic target for these patients.
A case is presented of a patient with metastatic IMT in complete response to treatment with alectinib, maintained for over 4 years.

炎性肌纤维母细胞瘤（Inflammatory Myofibroblastic Tumor, IMT）是一种罕见的病变，归类于软组织肉瘤范畴。其属于中间型恶性肿瘤，极少表现为转移性病变。临床首选治疗方案为手术，但当肿瘤因局部位置特殊无法实施手术，或病变已发生转移时，则不适合采用手术治疗。约50%的IMT可检测到ALK基因易位（ALK translocation），可为此类患者提供治疗靶点。
本文报告1例转移性IMT患者，经阿来替尼（alectinib）治疗后达到完全缓解，且疗效维持超过4年。